Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | Both sides next revision |
pharmaceutical_companies:shanghai_zerun_biotechnology [2022/11/01 04:40]
liam | pharmaceutical_companies:shanghai_zerun_biotechnology [2024/11/17 20:12] (current)
liam [Research and development] |
|---|
| |
| In July 2021, the [[:Coalition for Epidemic Preparedness Innovations]] (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop [[:COVID-19 vaccines|COVID-19 vaccine]] candidates against both the original strain of [[:SARS-CoV-2]] and its newer variants.((//CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine.// (2021, July 21). CEPI. https://web.archive.org/web/20220611060746/https://cepi.net/news_cepi/cepi-partners-with-shanghai-zerun-biotech-to-develop-covid-19-variant-vaccine/)) As of October 2022, CEPI had provided up to $25.1 million USD towards a candidate called 202-CoV, but had ceased further funding.((//Who we are.// CEPI. Retrieved October 19, 2022, from https://web.archive.org/web/20221019165747/https://cepi.net/about/whoweare/)) The chimeric protein candidate remains in Phase I clinical trials. | In July 2021, the [[:Coalition for Epidemic Preparedness Innovations]] (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop [[:COVID-19 vaccines|COVID-19 vaccine]] candidates against both the original strain of [[:SARS-CoV-2]] and its newer variants.((//CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine.// (2021, July 21). CEPI. https://web.archive.org/web/20220611060746/https://cepi.net/news_cepi/cepi-partners-with-shanghai-zerun-biotech-to-develop-covid-19-variant-vaccine/)) As of October 2022, CEPI had provided up to $25.1 million USD towards a candidate called 202-CoV, but had ceased further funding.((//Who we are.// CEPI. Retrieved October 19, 2022, from https://web.archive.org/web/20221019165747/https://cepi.net/about/whoweare/)) The chimeric protein candidate remains in Phase I clinical trials. |
| | |
| | ===== External links ===== |
| | |
| | * [[https://wiki.whiteroseintelligence.com/en/Shanghai-Zerun-Biotechnology|White Rose Wiki]] |
